Government limits trade margin on five medical devices from price to distributor level to 70 percent

The demand for medical equipment is increasing continuously due to the increasing cases of COVID-19 pandemic, keeping in view the demand, the government has decided to regularize their prices for affordable healthcare and COVID-19 management. Under this, keeping in view the wider public interest, the National Pharmaceutical Pricing Agency (NPPA) has issued a notification dated 13.07. Under this, the trade margin has been fixed at the distribution level from the price of (1) pulse oximeter, (2) blood pressure monitoring machine, (3) nebulizer, (4) digital thermometer, and (5) glucometer to a maximum of 70 percent. . Earlier, in February 2019, the NPPA had capped the trade margin on anti-cancer drugs and on June 3, 2021, the trade margin cap for oxygen concentrators. Based on the notification issued for notified trade margin, NPPA has directed the manufacturers/importers to report the revised MRP within seven days. Thereafter the revised MRP will be publicly communicated by the NPPA. The revised prices will be effective from 20 July 2021.
Every retailer, dealer, hospital and institution shall display the price list of these medical devices in a specified part of the business premises at the price decided by the manufacturer so that the information is easily accessible to any person. The manufacturers/importers who do not comply with the revised MRP after fixing the trade margin shall be subject to the provisions of the Essential Commodities Act, 1955 along with the Drugs (Prices Control) Order, 2013 with an additional penalty of up to 100% at the rate of 15 per cent interest. The amount has to be deposited. The State Drug Controller (SDC) will be responsible for ensuring and monitoring the compliance of these orders. Under which it will be his responsibility that no manufacturer, distributor, retailer will sell these medical devices to any consumer at a price exceeding the revised MRP. So that black marketing can be stopped.
This order will remain in force till 31 January 2022. If necessary, review can be done during this period.

nd for medical equipment is increasing continuously due to the increasing cases of COVID-19 pandemic, keeping in view the demand, the government has decided to regularize their prices for affordable healthcare and COVID-19 management. Under this, keeping in view the wider public interest, the National Pharmaceutical Pricing Agency (NPPA) has issued a notification dated 13.07. Under this, the trade margin has been fixed at the distribution level from the price of (1) pulse oximeter, (2) blood pressure monitoring machine, (3) nebulizer, (4) digital thermometer, and (5) glucometer to a maximum of 70 percent. . Earlier, in February 2019, the NPPA had capped the trade margin on anti-cancer drugs and on June 3, 2021, the trade margin cap for oxygen concentrators. Based on the notification issued for notified trade margin, NPPA has directed the manufacturers/importers to report the revised MRP within seven days. Thereafter the revised MRP will be publicly communicated by the NPPA. The revised prices will be effective from 20 July 2021.

Every retailer, dealer, hospital and institution shall display the price list of these medical devices in a specified part of the business premises at the price decided by the manufacturer so that the information is easily accessible to any person. The manufacturers/importers who do not comply with the revised MRP after fixing the trade margin shall be subject to the provisions of the Essential Commodities Act, 1955 along with the Drugs (Prices Control) Order, 2013 with an additional penalty of up to 100% at the rate of 15 per cent interest. The amount has to be deposited. The State Drug Controller (SDC) will be responsible for ensuring and monitoring the compliance of these orders. Under which it will be his responsibility that no manufacturer, distributor, retailer will sell these medical devices to any consumer at a price exceeding the revised MRP. So that black marketing can be stopped.

This order will remain in force till 31 January 2022. If necessary, review can be done during this period.